EG21437A - Method for preparing magnesium omeprazole compounds useful for inhibiting gastric acid sectretion - Google Patents

Method for preparing magnesium omeprazole compounds useful for inhibiting gastric acid sectretion

Info

Publication number
EG21437A
EG21437A EG40794A EG40794A EG21437A EG 21437 A EG21437 A EG 21437A EG 40794 A EG40794 A EG 40794A EG 40794 A EG40794 A EG 40794A EG 21437 A EG21437 A EG 21437A
Authority
EG
Egypt
Prior art keywords
sectretion
compounds useful
gastric acid
magnesium omeprazole
preparing magnesium
Prior art date
Application number
EG40794A
Other languages
English (en)
Original Assignee
Aktebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG21437(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aktebolaget Astra filed Critical Aktebolaget Astra
Application granted granted Critical
Publication of EG21437A publication Critical patent/EG21437A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Contacts (AREA)
  • Conductive Materials (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Powder Metallurgy (AREA)
  • Medicinal Preparation (AREA)
EG40794A 1993-07-09 1994-07-07 Method for preparing magnesium omeprazole compounds useful for inhibiting gastric acid sectretion EG21437A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Publications (1)

Publication Number Publication Date
EG21437A true EG21437A (en) 2001-10-31

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
EG40794A EG21437A (en) 1993-07-09 1994-07-07 Method for preparing magnesium omeprazole compounds useful for inhibiting gastric acid sectretion

Country Status (41)

Country Link
US (1) US5900424A (de)
EP (2) EP0707580B1 (de)
JP (2) JP3635432B2 (de)
KR (1) KR100353783B1 (de)
CN (1) CN1064680C (de)
AT (1) ATE212628T1 (de)
AU (1) AU679766B2 (de)
BR (1) BR9406940A (de)
CA (1) CA2166794C (de)
CZ (1) CZ288933B6 (de)
DE (2) DE69429774T2 (de)
DK (1) DK0707580T3 (de)
DZ (1) DZ1792A1 (de)
EE (1) EE03127B1 (de)
EG (1) EG21437A (de)
ES (1) ES2100136T3 (de)
FI (1) FI114154B (de)
GR (1) GR970300015T1 (de)
HR (1) HRP940385B1 (de)
HU (1) HU226861B1 (de)
IL (1) IL110190A (de)
IS (1) IS2075B (de)
MA (1) MA23257A1 (de)
MX (1) MX9405217A (de)
MY (1) MY113274A (de)
NO (1) NO308702B1 (de)
NZ (1) NZ268693A (de)
PL (1) PL175999B1 (de)
PT (1) PT707580E (de)
RU (1) RU2139868C1 (de)
SA (1) SA94150058B1 (de)
SE (1) SE9302396D0 (de)
SG (1) SG52464A1 (de)
SI (1) SI0707580T1 (de)
SK (1) SK281230B6 (de)
TN (1) TNSN94079A1 (de)
TW (1) TW504509B (de)
UA (1) UA43343C2 (de)
WO (1) WO1995001977A1 (de)
YU (1) YU49193B (de)
ZA (1) ZA944933B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
DK1078628T3 (da) 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
US6403616B1 (en) 1998-11-18 2002-06-11 Astrazeneca Ab Chemical process and pharmaceutical formulation
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030212274A1 (en) * 2000-05-15 2003-11-13 Bakthavathsalan Vijayaraghavan Novel amorphous form of omeprazole salts
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
WO2004099181A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
RU2257890C2 (ru) * 2003-10-06 2005-08-10 Марио Атилио Лос Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8658216B2 (en) 2004-12-23 2014-02-25 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
EP1845982A2 (de) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Durch ein nichtwässriges schichtungsverfahren hergestellte stabile orale benzimidaziol-zusammensetzungen
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
EP1801110A1 (de) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Argininsalz des Esomeprazols
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP2046334B1 (de) 2006-07-25 2014-05-21 Vecta Ltd. Zusammensetzungen und verfahren zur hemmung von magensäuresekretion anhand von derivaten kleiner dicarbonsäuren in kombination mit ppi
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP1947099A1 (de) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Verfahren zur Entfernung von Lösungsmitteln in Omeprazol-Salzen
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009132980A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2147918A1 (de) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Verfahren zur Herstellung von S-Omeprazol-Magnesium in einer stabilen Form
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (de) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Säurelabile Arzneimittelformulierungen
EP2601947A1 (de) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
MY113274A (en) 2002-01-31
PT707580E (pt) 2002-06-28
IS4186A (is) 1995-01-10
NO308702B1 (no) 2000-10-16
NZ268693A (en) 1997-05-26
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
DE707580T1 (de) 1997-09-04
AU7198194A (en) 1995-02-06
NO960068L (no) 1996-01-05
DE69429774D1 (de) 2002-03-14
CA2166794C (en) 1997-03-04
HK1008329A1 (en) 1999-05-07
AU679766B2 (en) 1997-07-10
RU2139868C1 (ru) 1999-10-20
JPH08512315A (ja) 1996-12-24
HRP940385B1 (en) 2003-06-30
HUT75314A (en) 1997-05-28
FI114154B (fi) 2004-08-31
CZ6996A3 (en) 1996-05-15
IS2075B (is) 2005-12-15
GR970300015T1 (en) 1997-05-31
KR100353783B1 (ko) 2004-04-03
US5900424A (en) 1999-05-04
SI0707580T1 (en) 2002-06-30
EE03127B1 (et) 1998-10-15
EP1164132A2 (de) 2001-12-19
BR9406940A (pt) 1996-09-10
SE9302396D0 (sv) 1993-07-09
IL110190A0 (en) 1994-10-21
JP2002105072A (ja) 2002-04-10
ES2100136T1 (es) 1997-06-16
EP1164132A3 (de) 2002-01-02
EP0707580B1 (de) 2002-01-30
HU9503873D0 (en) 1996-02-28
DZ1792A1 (fr) 2002-02-17
PL312440A1 (en) 1996-04-29
SA94150058B1 (ar) 2006-06-20
HRP940385A2 (en) 1997-02-28
FI960101A0 (fi) 1996-01-09
DE69429774T2 (de) 2002-11-14
ATE212628T1 (de) 2002-02-15
PL175999B1 (pl) 1999-03-31
FI960101L (fi) 1996-01-09
IL110190A (en) 2000-07-26
DK0707580T3 (da) 2002-04-15
UA43343C2 (uk) 2001-12-17
TNSN94079A1 (fr) 1995-04-25
SG52464A1 (en) 1998-09-28
EP0707580A1 (de) 1996-04-24
ZA944933B (en) 1995-02-20
YU43694A (sh) 1997-07-31
NO960068D0 (no) 1996-01-05
TW504509B (en) 2002-10-01
CN1126993A (zh) 1996-07-17
JP3635432B2 (ja) 2005-04-06
WO1995001977A1 (en) 1995-01-19
CZ288933B6 (cs) 2001-09-12
MA23257A1 (fr) 1995-04-01
MX9405217A (es) 1995-01-31
HU226861B1 (en) 2009-12-28
YU49193B (sh) 2004-09-03
CN1064680C (zh) 2001-04-18
JP3878826B2 (ja) 2007-02-07
ES2100136T3 (es) 2002-09-01

Similar Documents

Publication Publication Date Title
HUT75314A (en) Magnesium salt of omeprazole
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
HUT50842A (en) Process for producing new diphosphonic acid derivatives and pharmaceutical compositions comprising same
CS38989A2 (en) Method of phenoxyacetamidoderivative production
HUT60918A (en) Process for producing compositions inhibiting production of gastric acid
HU9302528D0 (en) Method for producing substituted cyclohexane derivatives and another one for preparing medical preparatives containing said compounds
EP0404283A3 (de) 11-Beta-aryl-4-estrene, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AU661591B2 (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
HUT37794A (en) Process for producing new beta-carbolina-3-oxa-diazolyl derivatives and pharmaceutical compositions containing them
HUT46664A (en) Process for producing new dihydropyridineamide derivatives and pharmaceutical compositions comprising these compounds
AU5778894A (en) Process for producing alkoxyiminoacetamide compounds and the production of intermediate compounds used in the process
HU904582D0 (en) Process for producing amino-oligohydroxi derivatives and pharmaceutical preparatives containing those compounds
HUT69696A (en) Method for producing a novel physical modification of a carbamoylindole derivative and the pharmaceutical compositions comprising it
HU207979B (en) Process for producing 3,7,11-trimethyl-2e,4e-dodecadienic acid esters of high purity
HU9201664D0 (en) Process for the production of intermedier nizatidine and its derivatives